A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia Clinical Trial

Official title:

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01561898
• Other study ID #: CR012628
• Secondary ID: JNS007ER-JPN-S32
• Status: Completed
• Phase: Phase 3
• First received: March 22, 2012
• Last updated: September 14, 2012
• Start date: June 2006
• Est. completion date: October 2008

Study information

• Verified date: September 2012
• Source: Janssen Pharmaceutical K.K.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.

Description:

This is a 48-week, multicenter, open-label (all people know the identity of the intervention), non-controlled, arbitrary-dose study. The patients included in this study are those who participated in the preceding double-blind (neither physician nor patient knows the treatment that the patient receives) comparative trial (study JNS007ER-JPN-S31) of JNS007ER and completed the study, or those who remained in the study up to the evaluation at 2 weeks and discontinued the study after that for insufficient treatment efficacy. The study will assess the safety of JNS007ER in the clinical recommended dose range in a long term treatment. The dosage will be started at 6 mg/day, and it can be increased or decreased 3 mg at a time depending on the patient's symptom within the range of 3 mg/day to 12 mg/day. For dose adjustments, the investigator will evaluate the psychiatric symptoms before defining the dose change.

Detailed Description: Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 228
• Est. completion date: October 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with schizophrenia

• Patients who have given their own consent in writing to participate in the study

• Patients untreated with antipsychotics within 28 days before the screening test

• Patients who have completed Study JNS007ER-JPN-S31, or those who continued the study at least up to the evaluation at 2 weeks and subsequently discontinued the study due to insufficient efficacy

• Patients participating in Study JNS007ER-JPN-S31 and whose ratio of treatment to the evaluation at 2 weeks is =75%

Exclusion Criteria:

• Patients diagnosed with a mental disease other than schizophrenia

• A total PANSS score > 120 at baseline

• Substance-related disorders

• Parkinson's disease complications

• Current or a past history of convulsive disease such as epilepsy

• Current or a past history of cerebrovascular accident

• Diabetes mellitus

• Significant hepatic or renal impairment

• Significant cardiovascular disorders

• Abnormal results of hematological examination, blood chemistry test and urinalysis at screening

• Pregnant women, breast-feeding mothers, and patients who wish pregnancy during the study period or those whose pregnancy test at screening was positive

• Contraindications to risperidone products

• Patients who discontinued Study JNS007ER-JPN-S31 due to an adverse event not related to the underlying disease

• Patients judged inadequate by the investigator to participate in the study

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• Paliperidone extended-release (JNS007ER)
Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Pharmaceutical K.K.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events	The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.	48 weeks	No
Secondary	Change From Baseline in Positive and Negative Syndrome Scale (PANSS)	PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).	Baseline, Week 48	No
Secondary	Change From Baseline in Clinical Global Impression - Severity (CGI-S)	The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients".	Baseline, Week 48	No